IL28B single nucleotide polymorphisms in the treatment of hepatitis C

被引：92

作者：

Lange, Christian M. ^{[1
,2
]}

Zeuzem, Stefan ^{[1
]}

机构：

[1] Klinikum JW Goethe Univ Frankfurt Main, Med Klin 1, D-60590 Frankfurt, Germany

[2] Univ Lausanne, Ctr Hosp Univ Vaudois, CH-1010 Lausanne, Switzerland

来源：

JOURNAL OF HEPATOLOGY | 2011年 / 55卷 / 03期

关键词：

Hepatitis C virus; Genome-wide association study; Single nucleotide polymorphism; Antiviral therapy; Directly acting antiviral agent; Individualized therapy; Personal medicine; Genomic medicine; Interferon-alpha; Interferon-lambda; IL28B; SUSTAINED VIROLOGICAL RESPONSE; INTERFERON PLUS RIBAVIRIN; GENOME-WIDE ASSOCIATION; GENETIC-VARIATION; INTERLEUKIN-28B GENOTYPE; SPONTANEOUS CLEARANCE; VIRAL RESPONSE; IFN-LAMBDA; VIRUS; THERAPY;

D O I：

10.1016/j.jhep.2011.03.006

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Recent genome-wide association studies (GWAS) have identified genetic variations near the IL28B gene which are strongly associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. Protective IL28B variations are strongly associated with on-treatment viral kinetics and approximately 2-fold increased sustained virologic response (SVR) rates in HCV genotype 1 and 4 patients. In HCV genotype 1 patients, IL28B variations were shown to be the strongest pre-treatment predictor of virologic response. In the treatment of HCV genotype 2 and 3 infected patients, IL28B variations play only a minor role. Preliminary data indicate that IL28B variations are also associated with treatment outcome of regimens, including directly acting antiviral (DAA) agents, though their impact seems to be attenuated compared to standard treatment. Here, we review these important findings and discuss possible implications for clinical decision making in the treatment of HCV infection. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

引用

页码：692 / 701

页数：10

共 85 条

[1] Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients [J].

Abe, Hiromi ;

Ochi, Hidenori ;

Maekawa, Toshiro ;

Hayes, C. Nelson ;

Tsuge, Masataka ;

Miki, Daiki ;

Mitsui, Fukiko ;

Hiraga, Nobuhiko ;

Imamura, Michio ;

Takahashi, Shoichi ;

Ohishi, Waka ;

Arihiro, Koji ;

Kubo, Michiaki ;

Nakamura, Yusuke ;

Chayama, Kazuaki .

JOURNAL OF HEPATOLOGY, 2010, 53 (03) :439-443

[2] Hepatitis C Pharmacogenetics: State of the Art in 2010 [J].

Afdhal, Nezam H. ;

McHutchison, John G. ;

Zeuzem, Stefan ;

Mangia, Alessandra ;

Pawlotsky, Jean-Michel ;

Murray, Jeffrey S. ;

Shianna, Kevin V. ;

Tanaka, Yasuhito ;

Thomas, David L. ;

Booth, David R. ;

Goldstein, David B. .

HEPATOLOGY, 2011, 53 (01) :336-345

[3] Amino Acid Substitution in Hepatitis C Virus Core Region and Genetic Variation Near the Interleukin 28B Gene Predict Viral Response to Telaprevir with Peginterferon and Ribavirin [J].

Akuta, Norio ;

Suzuki, Fumitaka ;

Hirakawa, Miharu ;

Kawamura, Yusuke ;

Yatsuji, Hiromi ;

Sezaki, Hitomi ;

Suzuki, Yoshiyuki ;

Hosaka, Tetsuya ;

Kobayashi, Masahiro ;

Kobayashi, Mariko ;

Saitoh, Satoshi ;

Arase, Yasuji ;

Ikeda, Kenji ;

Chayama, Kazuaki ;

Nakamura, Yusuke ;

Kumada, Hiromitsu .

HEPATOLOGY, 2010, 52 (02) :421-429

[4] A haplotype map of the human genome [J].

Altshuler, D ;

Brooks, LD ;

Chakravarti, A ;

Collins, FS ;

Daly, MJ ;

Donnelly, P ;

Gibbs, RA ;

Belmont, JW ;

Boudreau, A ;

Leal, SM ;

Hardenbol, P ;

Pasternak, S ;

Wheeler, DA ;

Willis, TD ;

Yu, FL ;

Yang, HM ;

Zeng, CQ ;

Gao, Y ;

Hu, HR ;

Hu, WT ;

Li, CH ;

Lin, W ;

Liu, SQ ;

Pan, H ;

Tang, XL ;

Wang, J ;

Wang, W ;

Yu, J ;

Zhang, B ;

Zhang, QR ;

Zhao, HB ;

Zhao, H ;

Zhou, J ;

Gabriel, SB ;

Barry, R ;

Blumenstiel, B ;

Camargo, A ;

Defelice, M ;

Faggart, M ;

Goyette, M ;

Gupta, S ;

Moore, J ;

Nguyen, H ;

Onofrio, RC ;

Parkin, M ;

Roy, J ;

Stahl, E ;

Winchester, E ;

Ziaugra, L ;

Shen, Y .

NATURE, 2005, 437 (7063) :1299-1320

[5] Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo [J].

Ank, N ;

West, H ;

Bartholdy, C ;

Eriksson, K ;

Thomsen, AR ;

Paludan, SR .

JOURNAL OF VIROLOGY, 2006, 80 (09) :4501-4509

[6] Type III IFNs: New layers of complexity in innate antiviral immunity [J].

Ank, Nina ;

Paludan, Soren R. .

BIOFACTORS, 2009, 35 (01) :82-87

[7] Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes [J].

Antonio Montes-Cano, Marco ;

Raul Garcia-Lozano, Jose ;

Abad-Molina, Cristina ;

Romero-Gomez, Manuel ;

Barroso, Natalia ;

Aguilar-Reina, Jose ;

Nunez-Roldan, Antonio ;

Francisca Gonzalez-Escribano, Maria .

HEPATOLOGY, 2010, 52 (01) :33-37

[8] Lack of Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2) and KIR2DL2 Is Associated with Poor Responses to Therapy of Recurrent Hepatitis C Virus in Liver Transplant Recipients [J].

Askar, Medhat ;

Avery, Robin ;

Corey, Rebecca ;

Lopez, Rocio ;

Thomas, Dawn ;

Pidwell, Diane ;

Eghtesad, Bijan ;

Miller, Charles ;

Fung, John ;

Zein, Nizar N. .

LIVER TRANSPLANTATION, 2009, 15 (11) :1557-1563

[9]

Bacon BR, 2010, HEPATOLOGY, V52, p430A

[10] Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy [J].

Berg, T ;

Sarrazin, C ;

Herrmann, E ;

Hinrichsen, H ;

Gerlach, T ;

Zachoval, R ;

Wiedenmann, B ;

Hopf, U ;

Zeuzem, S .

HEPATOLOGY, 2003, 37 (03) :600-609

← 1 2 3 4 5 6 7 8 9 →